— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.
— Total revenue stood at $1.96 million vs. $3.68 million expected.

— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.
— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.
— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Earnings Preview: What to look for when Kroger (KR) reports Q1 2025 results
The Kroger Co. (NYSE: KR) is expected to report its first-quarter financial results next week. Customer engagement remained stable last year, driven by high-quality products and tailored promotional offers. Recently,
Adobe (ADBE) Q2 adjusted earnings rise on higher revenues
Adobe Inc. (NASDAQ: ADBE) on Thursday reported an increase in revenue and adjusted profit for the second quarter of 2025, amid continued growth in its subscription-based business. The design software
ORCL Earnings: Highlights of Oracle’s Q4 2025 financial report
Technology giant Oracle Corporation (NYSE: ORCL) has reported higher revenues and adjusted earnings for the fourth quarter of 2025. Total revenues increased to $15.9 billion in the May quarter from